HALOZYME THERAPEUTICS, INC. 8-K

What Happened Halozyme Therapeutics, Inc. held its Annual Meeting of Stockholders on May 5, 2026 and reported the results in an 8‑K filed May 7, 2026. Of 118,474,300 shares outstanding as of the record date, 104,138,244 shares were represented at the meeting. Two Class I directors — Bernadette Connaughton and Matthew L. Posard — were elected for three‑year terms. The advisory "say‑on‑pay" vote on executive compensation was approved, and stockholders ratified Ernst & Young LLP as the company's independent registered public accounting firm for fiscal 2026.

Key Details

• Shares outstanding (record date): 118,474,300; shares represented at meeting: 104,138,244.
• Director election votes:
  • Bernadette Connaughton — For: 89,053,734; Against: 5,068,160; Abstain: 127,131; Broker non‑votes: 9,889,219.
  • Matthew L. Posard — For: 82,739,433; Against: 10,236,878; Abstain: 1,272,714; Broker non‑votes: 9,889,219.
• Advisory vote on named executive officer compensation: For 84,682,518; Against 9,311,426; Abstain 255,081; Broker non‑votes 9,889,219 (proposal approved).
• Ratification of auditor (Ernst & Young LLP): For 103,197,579; Against 849,433; Abstain 91,232 (proposal approved).

Why It Matters These results confirm board composition and shareholder support for Halozyme’s executive pay policies and external auditor for 2026. Re-election of the two Class I directors preserves board continuity, the approved say‑on‑pay indicates majority investor support for compensation practices, and auditor ratification ensures continuity in financial reporting oversight. Investors can view this 8‑K as a routine governance update with no change in management or corporate control.